JP2022520859A - レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療 - Google Patents

レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療 Download PDF

Info

Publication number
JP2022520859A
JP2022520859A JP2021548200A JP2021548200A JP2022520859A JP 2022520859 A JP2022520859 A JP 2022520859A JP 2021548200 A JP2021548200 A JP 2021548200A JP 2021548200 A JP2021548200 A JP 2021548200A JP 2022520859 A JP2022520859 A JP 2022520859A
Authority
JP
Japan
Prior art keywords
rorγ
cells
cancer
tumor
jte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021548200A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520859A5 (https=
Inventor
レヤ，タニシュサ
ライトル，ニッキー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2022520859A publication Critical patent/JP2022520859A/ja
Publication of JP2022520859A5 publication Critical patent/JP2022520859A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021548200A 2019-02-20 2020-02-20 レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療 Pending JP2022520859A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962808231P 2019-02-20 2019-02-20
US62/808,231 2019-02-20
US201962881890P 2019-08-01 2019-08-01
US62/881,890 2019-08-01
US201962897202P 2019-09-06 2019-09-06
US62/897,202 2019-09-06
US201962903595P 2019-09-20 2019-09-20
US62/903,595 2019-09-20
US202062959607P 2020-01-10 2020-01-10
US62/959,607 2020-01-10
PCT/US2020/019118 WO2020172467A1 (en) 2019-02-20 2020-02-20 Treatment for retinoic acid receptor-related orphan receptor ɣ (rorɣ)-dependent cancers

Publications (2)

Publication Number Publication Date
JP2022520859A true JP2022520859A (ja) 2022-04-01
JP2022520859A5 JP2022520859A5 (https=) 2023-02-28

Family

ID=72144161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021548200A Pending JP2022520859A (ja) 2019-02-20 2020-02-20 レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療

Country Status (5)

Country Link
US (1) US20220202811A1 (https=)
EP (1) EP3927329A4 (https=)
JP (1) JP2022520859A (https=)
CN (1) CN113710239A (https=)
WO (1) WO2020172467A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149786A1 (en) * 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2024229569A1 (en) * 2023-05-09 2024-11-14 11949098 Canada Inc. Inverse agonists of rar related orphan receptors (rors)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513123A (ja) * 2015-03-12 2018-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9629910B2 (en) * 2011-03-22 2017-04-25 The Brigham And Women's Hospital, Inc. Use of Th9 cells and IL-9 for the treatment of melanoma
WO2012158784A2 (en) * 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
US9359315B2 (en) * 2013-09-10 2016-06-07 Arrien Pharmaceuticals Llc Substituted 2,3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
WO2015083130A1 (en) * 2013-12-06 2015-06-11 Aurigene Discovery Technologies Limited Fused pyridine and pyrimidine derivatives as ror gamma modulators
JP6564029B2 (ja) * 2014-10-14 2019-08-21 ヴァイティー ファーマシューティカルズ，エルエルシー Ｒｏｒ−ガンマのジヒドロピロロピリジン阻害剤
SI3294713T1 (sl) * 2015-05-15 2021-08-31 Aurigene Discovery Technologies Limited, Nadomeščene spojine tetrahidrokinolinona kot ROR gama modulatorji
WO2017079120A1 (en) * 2015-11-04 2017-05-11 The Scripps Research Institute Ror gamma agonists as enhancers of protective immunity
WO2017127442A1 (en) * 2016-01-18 2017-07-27 The Regents Of The University Of California Methods for treating cancer with rorgamma inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513123A (ja) * 2015-03-12 2018-05-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VRAJESH B. PANDYA ET AL.: "Combating Autoimmune Diseases With Retinoic Acid Receptor-Related Orphan Receptor-γ (RORγ or RORc)", JOURNAL OF MEDICINAL CHEMISTRY, vol. 61, no. 24, JPN6023053663, 2018, pages 10976 - 10995, ISSN: 0005406964 *

Also Published As

Publication number Publication date
CN113710239A (zh) 2021-11-26
EP3927329A4 (en) 2022-11-23
WO2020172467A1 (en) 2020-08-27
EP3927329A1 (en) 2021-12-29
US20220202811A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
Bai et al. CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy
Morel et al. EZH2 inhibition activates a dsRNA–STING–interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
Nian et al. Interleukin-34-orchestrated tumor-associated macrophage reprogramming is required for tumor immune escape driven by p53 inactivation
Zhang et al. FOSL1 promotes metastasis of head and neck squamous cell carcinoma through super-enhancer-driven transcription program
Grauel et al. TGFβ-blockade uncovers stromal plasticity in tumors by revealing the existence of a subset of interferon-licensed fibroblasts
Chen et al. The aged tumor microenvironment limits T cell control of cancer
Qiu et al. Transcription elongation machinery is a druggable dependency and potentiates immunotherapy in glioblastoma stem cells
Pan et al. EHBP1L1 drives immune evasion in renal cell carcinoma through binding and stabilizing JAK1
CN115427585A (zh) 用于鉴定功能性疾病特异性调节性t细胞的方法
Liang et al. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression
Lehrich et al. Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancers
Cao et al. Interferon-γ-stimulated antigen-presenting cancer-associated fibroblasts hinder neoadjuvant chemoimmunotherapy efficacy in lung cancer
Li et al. Aurora A kinase inhibition induces accumulation of SCLC tumor cells in mitosis with restored interferon signaling to increase response to PD-L1
Portale et al. C/EBPβ-dependent autophagy inhibition hinders NK cell function in cancer
JP2024544003A (ja) 急性骨髄性白血病を治療する方法
Paul et al. Cooperation between the Hippo and MAPK pathway activation drives acquired resistance to TEAD inhibition
Pedretti et al. Harnessing STING Signaling and Natural Killer Cells Overcomes PARP Inhibitor Resistance in Homologous Recombination–Deficient Breast Cancer
Cai et al. Integrative analysis of immunogenic PANoptosis and experimental validation of cinobufagin-induced activation to enhance glioma immunotherapy
Zhang et al. A programmed cell death-related model based on machine learning for predicting prognosis and immunotherapy responses in patients with lung adenocarcinoma
Monti et al. Impaired activation of plasmacytoid dendritic cells via toll-like receptor 7/9 and STING is mediated by melanoma-derived immunosuppressive cytokines and metabolic drift
Pan et al. TGF-β-p-STAT1-LAIR2 axis has a “self-rescue” role for exhausted CD8+ T cells in hepatocellular carcinoma
Mondal et al. Brd7 loss reawakens dormant metastasis initiating cells in lung by forging an immunosuppressive niche
Tasiheng et al. DNA hypo-methylation and expression of GBP4 induces T cell exhaustion in pancreatic cancer
Zhang et al. SIN3B loss heats up cold tumor microenvironment to boost immunotherapy in pancreatic cancer
JP2022520859A (ja) レチノイン酸受容体関連オーファン受容体γ（ＲＯＲγ）依存性がんのための治療

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20211102

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20211102

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230217

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240327

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240903